PPARG2 Pro12Ala and TNFα -308G>A Polymorphisms Are Not Associated with Heart Failure Development in Patients with Ischemic Heart Disease after Coronary Artery Bypass Grafting

Table 1

Initial characteristics of the investigated groups.

	HF	Non-HF	P
	(n=78)	(n=44)
Age (y)	65.1 ± 8.4	59.6 ± 8.7	NS
BMI (kg/m^2)	27.0 ± 3.5	27.9 ± 3.4	NS
Smokers	16 (20%)	4 (9%)	NS
Hypertension	48 (62%)	28 (63%)	NS
History of MI	35 (45%)	15 (35%)	NS
Systolic BP (mmHg)	132.2 ± 12.3	127.7 ± 9.0	0.035
Diastolic BP (mmHg)	79.5 ± 5.0	79.2 ± 4.70	NS
LVEDV (cm)	5.2 ± 0.3	5.1 ± 0.8	NS
LV EF (%)	59 ± 4.5	59 ± 3.5	NS
6-MWT (m)	405 ± 62	446 ± 63	0.0007
Blood count:
RBC	4.3 ± 0.7	4.58 ± 0.6	0.031
HGB	13.3 ± 2.0	14 ± 1.9	NS
HCT	38.6 ± 5.8	40.32 ± 5.3	NS
WBC	7.9 ± 3.0	7.42 ± 2.5	NS
PLT	192.8 ± 59.9	186.64 ± 46.5	NS
Electrolytes:
Na (mmol/L)	139.8 ± 14.7	141.8 ± 2.8	NS
K (mmol/L)	4.5 ± 0.4	4.5 ± 0.4	NS
CRP (mg/L)	7.1 ± 8.1	6.6 ± 9.0	NS
TNF (pg/mL)	3.3 ± 3.9	2.6 ± 3.8	NS
IL-6 (pg/mL)	9.4 ± 5.4	8.6 ± 6.0	NS
NT-proBNP (pg/mL)	212.4 ± 101	198.3 ± 111	NS
eGFR (mL/min/1.73m^2)	74 ± 13.1	77.4 ± 11.0	NS
Total cholesterol (mmol/L)	4.1 ± 0.9	4.0 ± 0.8	NS
LDL-cholesterol (mmol/L)	2.2 ± 0.8	2.2 ± 0.7	NS
HDL-cholesterol (mmol/L)	1.4 ± 0.3	1.2 ± 0.3	0.016
Triglycerides (mmol/L)	1.3 ± 0.6	1.4 ± 0.6	NS
Medications:
Aspirin	100%	100%	NS
Beta-blockers	100%	100%	NS
ACE-I	91%	93%	NS
ARB	7 %	0 %	NS
Aldosterone antagonists	11 %	0 %	0.007
Diuretics	19 %	9 %	NS
Statins	99 %	98%	NS